Abbott Laboratories $ABT Shares Acquired by Rathbones Group PLC

Rathbones Group PLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 3.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,116,386 shares of the healthcare product maker’s stock after acquiring an additional 107,648 shares during the quarter. Abbott Laboratories accounts for approximately 1.2% of Rathbones Group PLC’s investment portfolio, making the stock its 15th biggest holding. Rathbones Group PLC’s holdings in Abbott Laboratories were worth $390,452,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Charles Schwab Trust Co lifted its holdings in Abbott Laboratories by 109.8% during the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after purchasing an additional 15,394 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in Abbott Laboratories in the 3rd quarter valued at about $185,640,000. Asset Management One Co. Ltd. increased its stake in Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after buying an additional 19,966 shares in the last quarter. AE Wealth Management LLC raised its holdings in shares of Abbott Laboratories by 20.8% during the third quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after acquiring an additional 11,264 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in shares of Abbott Laboratories by 6.1% during the third quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

NYSE:ABT opened at $102.84 on Monday. Abbott Laboratories has a 52 week low of $100.88 and a 52 week high of $139.06. The stock’s fifty day moving average is $109.48 and its two-hundred day moving average is $120.94. The company has a market capitalization of $179.11 billion, a P/E ratio of 27.65, a P/E/G ratio of 1.64 and a beta of 0.79. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insiders Place Their Bets

In other news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares of the company’s stock, valued at $2,846,504.24. This trade represents a 2.32% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of several recent research reports. Piper Sandler lowered their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Daiwa Securities Group cut their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Royal Bank Of Canada reduced their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $135.68.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.